Preliminary Amarin (NASDAQ:AMRN) Q1 numbers show revenue of about $150M vs. estimates for roughly $130M.
Cash and equivalents of $620M, with less than $50M still due on its royalty-like debt instrument.
Shares are up 7.5% after hours.
https://seekingalpha.com/news/3560317-amarin-reports-q1-vascepa-sales-of-150m
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.